Loading...
Loading...
Browse all stories on DeepNewz
VisitSyndax Secures FDA Approval for Revuforj®, First Menin Inhibitor for Relapsed Acute Leukemia, Shares Rise 4.3%
Nov 18, 2024, 06:16 PM
Syndax Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for its leukemia treatment, Revuforj® (revumenib). This drug is notable for being the first and only menin inhibitor approved for treating both adult and pediatric patients with relapsed or refractory acute leukemia featuring a KMT2A translocation. The approval marks a significant achievement for Syndax, especially following previous disappointments in other acute leukemia indications. Following the announcement, shares of Syndax ($SNDX) rose by 4.3% in pre-market trading.
View original story
Markets
No • 50%
Yes • 50%
Sales data from Syndax Pharmaceuticals' financial reports
No • 50%
Yes • 50%
FDA announcements and Syndax Pharmaceuticals press releases
Yes • 50%
No • 50%
Stock price data from financial markets such as NASDAQ or NYSE
Two • 25%
Three or more • 25%
None • 25%
One • 25%
FDA announcements and Syndax Pharmaceuticals press releases
Improved by 6-10 ranks • 25%
No change • 25%
Improved by more than 10 ranks • 25%
Improved by 1-5 ranks • 25%
Biotech sector rankings from financial and market analysis reports
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Market analysis reports and Syndax Pharmaceuticals' financial disclosures